COVID-19 and hepatic damage: what we know?

被引:3
|
作者
Mameli, Simone [1 ]
Marcialis, Maria A. [2 ]
Bassareo, Pier P. [3 ,4 ]
Fanos, Vassilios [2 ]
机构
[1] Univ Cagliari, Grad Sch Pediat, Cagliari, Italy
[2] Univ Cagliari, Neonatal Intens Care Unit, Cagliari, Italy
[3] Mater Misericordiae Univ Hosp, Dublin, Ireland
[4] Univ Coll Dublin, Our Ladys Childrens Hosp Crumlin, Dublin, Ireland
关键词
SARS-CoV-2; COVID-19; Liver; Liver diseases; Child; CORONAVIRUS DISEASE 2019; CLINICAL CHARACTERISTICS; SARS-COV; WUHAN; INSIGHTS; FEATURES;
D O I
10.23736/S0031-0808.21.04239-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION: Since the end of 2019, a new disease outbreak has been spreading worldwide, after starting from Wuhan, China. The viral pathogen responsible for the disease was named as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), and for the illness the acronym COVID-19 was coined (COronaVIrus Disease 2019). Viral pathogenesis, epidemiology, and clinics are still somewhat obscure, when occurring during childhood the most. The aim of this study was to evaluate the features of liver involvement and damage in course of COVID-19. EVIDENCE ACQUISITION: An insight into what is known as to COVID-19 and hepatic damage in adulthood as well as pediatric age was given. All the most relevant papers up to 15/10/2020 were identified and discussed. An extensive search strategy was carried out to identify all paper published from December 1st, 2019, to September 5, 2020, combining the key words "coronavirus," "coronavirus infection," "SARS-CoV-2," "COVID-19," "liver," "liver injury," "hepatic injury," "children," "pediatric" in key electronic bibliographic databases (PubMed, Google Scholar), following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. EVIDENCE SYNTHESIS: Establishing whether liver damage is due to a direct viral action or host immune system inflammatory reaction or consequence of the administered drugs or secondary to another organ failure (for example the heart) is difficult. What is sure is the fact that liver function should be checked at the time of admission to hospital and during hospitalization. CONCLUSIONS: In conclusion, liver involvement during COVID-19 is likely due to a multifactorial origin. An aberrant immune system reaction to SARS-CoV-2 is probably the most important underlying trigger, though more extended studies are needed for a definitive confirmation. The markers of liver injury should be carefully in each patient admitted for COVID-19: in fact, in case of altered hepatic markers, a specific therapy to protect liver is needed.
引用
收藏
页码:58 / 64
页数:7
相关论文
共 50 条
  • [31] Comment on:COVID-19 and Older Adults: What We Know
    Famularo, Giuseppe
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 68 (10) : 2197 - 2197
  • [32] What we know about COVID-19 and its treatment
    Yakut, Zatiye Ayca Cevikelli
    Sakarcan, Sinem
    Sener, Goksel
    JOURNAL OF RESEARCH IN PHARMACY, 2020, 24 (05): : 602 - 616
  • [33] COVID-19 in dental care: What do we know?
    Chmielewski, Marek
    Zalachowska, Oliwia
    Rybakowska, Weronika
    Komandera, Dominika
    Knura, Agata
    Albert, Adrian
    Kostanowicz, Julia
    Garbacz, Katarzyna
    JOURNAL OF ORAL MICROBIOLOGY, 2021, 13 (01)
  • [34] Vasculitis and COVID-19: what do we have to know?
    Tamburello, Antonio
    Castelno, Laura
    Bizzi, Emanuele
    Caso, Francesco
    ITALIAN JOURNAL OF MEDICINE, 2020, 14 (04) : 213 - 215
  • [35] Erythema Multiforme and COVID-19: What Do We Know?
    Bennardo, Luigi
    Nistico, Steven Paul
    Dastoli, Stefano
    Provenzano, Eugenio
    Napolitano, Maddalena
    Silvestri, Martina
    Passante, Maria
    Patruno, Cataldo
    MEDICINA-LITHUANIA, 2021, 57 (08):
  • [36] COVID-19 vaccines and pregnancy: What do we know?
    Cottin, Judith
    Benevent, Justine
    Khettar, Sophie
    Lacroix, Isabelle
    THERAPIE, 2021, 76 (04): : 373 - 374
  • [37] COVID-19 and cancer: what we know so far
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2020, 17 : 336 - 336
  • [38] COVID-19 and Myositis: What We Know So Far
    Ahmad Saud
    R Naveen
    Rohit Aggarwal
    Latika Gupta
    Current Rheumatology Reports, 2021, 23
  • [39] COVID-19, gender and estroprogestins, what do we know?
    Fidecicchi, Tiziana
    Fruzzetti, Franca
    Lete Lasa, Luis Ignacio
    Calaf, Joaquim
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2022, 27 (01): : 67 - 74
  • [40] Lupus, vaccinations and COVID-19: What we know now
    Mason, Alice
    Anver, Himashi
    Lwin, May
    Holroyd, Christopher
    Faust, Saul N.
    Edwards, Christopher J.
    LUPUS, 2021, 30 (10) : 1541 - 1552